Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences
Trade with 70% Backtested Accuracy
Analyst Views on TNYA
About TNYA
About the author
Tenaya Therapeutics Plans 2026 Data Release for Heart Disease Gene Therapies
- Clinical Progress: Tenaya Therapeutics plans to release key clinical data for TN-201 and TN-401 in the first half of 2026, which is expected to provide new treatment hope for heart disease patients and further solidify the company's leadership in gene therapy.
- Funding Support: The company successfully raised $60 million in Q4 2025, ensuring sufficient operational funding through mid-2027, thereby enhancing its financial stability in gene therapy development.
- Regulatory Alignment: Tenaya aims to pursue regulatory alignment for pivotal studies of TN-201 and TN-401 in 2026, intending to accelerate the product launch process to meet the urgent market demand for innovative therapies.
- Safety Data: Both TN-201 and TN-401 demonstrated good tolerability in clinical trials with no dose-limiting toxicities observed, indicating their potential in treating genetic heart diseases and possibly laying a foundation for the company's future market performance.
Tenaya Shares Drop Following $60 Million Equity Raise
Stock Performance: Tenaya Therapeutics (TNYA) stock is experiencing a significant decline, trading down 37.44% at 85 cents, with a session volume of 42.39 million compared to the average of 3.51 million.
Public Offering Announcement: The company has priced an underwritten public offering of 50 million units at $1.20 each, aiming to raise $60 million to support the development of its clinical candidates, particularly TN-201 and TN-401.
Clinical Trial Updates: Interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy shows it was well tolerated, with improvements in arrhythmia burden and no serious adverse events reported.
FDA Notification: Tenaya Therapeutics has received notification from the FDA that the clinical hold on the MyPEAK-1 Phase 1b/2a trial of TN-201 has been lifted, allowing further development of the treatment for hypertrophic cardiomyopathy.
S&P 500 Declines 1%; Broadcom Reports Earnings Exceeding Expectations
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 350 points, while the Dow and S&P 500 also experienced losses of 0.45% and 1.04%, respectively.
Broadcom's Strong Earnings: Broadcom Inc. reported fourth-quarter revenue of $18.02 billion, exceeding expectations, and announced a 10% increase in its quarterly cash dividend.
Notable Stock Movements: cbdMD Inc. shares surged 126% after compliance news, while Canopy Growth Corp. rose 38% on potential regulatory changes. Conversely, Applied Therapeutics Inc. fell 44% following acquisition news.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.53%, while Asian markets closed higher, led by Japan's Nikkei gaining 1.37%.
Dow Gains More Than 100 Points as Lululemon Reports Strong Q3 Earnings
Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining 0.24% while the NASDAQ and S&P 500 fell by 0.34% and 0.13%, respectively.
Lululemon's Strong Earnings: Lululemon Athletica reported better-than-expected third-quarter earnings of $2.59 per share, surpassing estimates, and raised its full-year guidance.
Notable Stock Movements: cbdMD Inc shares surged 101% after compliance news, while Applied Therapeutics Inc saw a 48% drop following acquisition plans.
Global Market Trends: European and Asian markets closed higher, with the eurozone's STOXX 600 up 0.2% and Japan's Nikkei gaining 1.37%.
Tenaya Therapeutics Sets $60 Million Price for 50 Million Unit Offering, Clinical Hold on TN-201 Rescinded
Public Offering Announcement: Tenaya Therapeutics has priced a $60 million public offering of 50 million units at $1.20 each, with proceeds aimed at advancing clinical development of its gene therapies TN-201 and TN-401.
FDA Clinical Hold Lifted: The U.S. FDA has lifted the clinical hold on Tenaya's MyPEAK-1 trial for TN-201, allowing dosing to resume after addressing all FDA concerns and implementing protocol amendments for patient monitoring.
Regulatory Designations: TN-201 has received multiple designations from the FDA, including Fast Track and Orphan Drug status, highlighting its potential in treating genetic heart diseases.
Stock Performance: Tenaya's stock has fluctuated between $0.36 and $2.94 over the past year, currently trading at $1.24, reflecting an 8.82% decrease in pre-market trading.
Tenaya Therapeutics Sets Price for $60 Million Unit Offering
Public Offering Announcement: Tenaya Therapeutics (TNYA) announced the pricing of an underwritten public offering of 50 million shares.
Market Impact: The offering is expected to influence the company's stock performance and investor interest.
Tenaya Therapeutics Plans 2026 Data Release for Heart Disease Gene Therapies
- Clinical Progress: Tenaya Therapeutics plans to release key clinical data for TN-201 and TN-401 in the first half of 2026, which is expected to provide new treatment hope for heart disease patients and further solidify the company's leadership in gene therapy.
- Funding Support: The company successfully raised $60 million in Q4 2025, ensuring sufficient operational funding through mid-2027, thereby enhancing its financial stability in gene therapy development.
- Regulatory Alignment: Tenaya aims to pursue regulatory alignment for pivotal studies of TN-201 and TN-401 in 2026, intending to accelerate the product launch process to meet the urgent market demand for innovative therapies.
- Safety Data: Both TN-201 and TN-401 demonstrated good tolerability in clinical trials with no dose-limiting toxicities observed, indicating their potential in treating genetic heart diseases and possibly laying a foundation for the company's future market performance.
Tenaya Shares Drop Following $60 Million Equity Raise
Stock Performance: Tenaya Therapeutics (TNYA) stock is experiencing a significant decline, trading down 37.44% at 85 cents, with a session volume of 42.39 million compared to the average of 3.51 million.
Public Offering Announcement: The company has priced an underwritten public offering of 50 million units at $1.20 each, aiming to raise $60 million to support the development of its clinical candidates, particularly TN-201 and TN-401.
Clinical Trial Updates: Interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy shows it was well tolerated, with improvements in arrhythmia burden and no serious adverse events reported.
FDA Notification: Tenaya Therapeutics has received notification from the FDA that the clinical hold on the MyPEAK-1 Phase 1b/2a trial of TN-201 has been lifted, allowing further development of the treatment for hypertrophic cardiomyopathy.
S&P 500 Declines 1%; Broadcom Reports Earnings Exceeding Expectations
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 350 points, while the Dow and S&P 500 also experienced losses of 0.45% and 1.04%, respectively.
Broadcom's Strong Earnings: Broadcom Inc. reported fourth-quarter revenue of $18.02 billion, exceeding expectations, and announced a 10% increase in its quarterly cash dividend.
Notable Stock Movements: cbdMD Inc. shares surged 126% after compliance news, while Canopy Growth Corp. rose 38% on potential regulatory changes. Conversely, Applied Therapeutics Inc. fell 44% following acquisition news.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.53%, while Asian markets closed higher, led by Japan's Nikkei gaining 1.37%.
Dow Gains More Than 100 Points as Lululemon Reports Strong Q3 Earnings
Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining 0.24% while the NASDAQ and S&P 500 fell by 0.34% and 0.13%, respectively.
Lululemon's Strong Earnings: Lululemon Athletica reported better-than-expected third-quarter earnings of $2.59 per share, surpassing estimates, and raised its full-year guidance.
Notable Stock Movements: cbdMD Inc shares surged 101% after compliance news, while Applied Therapeutics Inc saw a 48% drop following acquisition plans.
Global Market Trends: European and Asian markets closed higher, with the eurozone's STOXX 600 up 0.2% and Japan's Nikkei gaining 1.37%.
Tenaya Therapeutics Sets $60 Million Price for 50 Million Unit Offering, Clinical Hold on TN-201 Rescinded
Public Offering Announcement: Tenaya Therapeutics has priced a $60 million public offering of 50 million units at $1.20 each, with proceeds aimed at advancing clinical development of its gene therapies TN-201 and TN-401.
FDA Clinical Hold Lifted: The U.S. FDA has lifted the clinical hold on Tenaya's MyPEAK-1 trial for TN-201, allowing dosing to resume after addressing all FDA concerns and implementing protocol amendments for patient monitoring.
Regulatory Designations: TN-201 has received multiple designations from the FDA, including Fast Track and Orphan Drug status, highlighting its potential in treating genetic heart diseases.
Stock Performance: Tenaya's stock has fluctuated between $0.36 and $2.94 over the past year, currently trading at $1.24, reflecting an 8.82% decrease in pre-market trading.
Tenaya Therapeutics Sets Price for $60 Million Unit Offering
Public Offering Announcement: Tenaya Therapeutics (TNYA) announced the pricing of an underwritten public offering of 50 million shares.
Market Impact: The offering is expected to influence the company's stock performance and investor interest.
